Wendy S.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Phase I Study of SIRPα-Directed Monoclonal Antibody BYON4228 Alone and with Rituximab in Relapsed/Refractory CD20+ B-cell Non-Hodgkin's Lymphoma
- Phase II Study of FDG-PET-Adapted Brentuximab Vedotin-Based Regimens in Advanced Hodgkin Lymphoma
- RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
Data & Insights
Has run more than one trial at 18 of 49 partner sites.
Specializations
Solid Tumor Oncology
Focus on advanced breast cancer, non‑small cell lung cancer, prostate cancer, urothelial carcinoma and renal cell carcinoma.
- Targeted therapy evaluation
- Immunotherapy combination strategies
- Biomarker‑driven patient selection
Research conducted at Radboud University Medical Center supports therapeutic innovation across multiple organ sites.
Hematologic Malignancies
Investigation of high‑risk acute myeloid leukemia, diffuse large B‑cell lymphoma, multiple myeloma and Waldenström macroglobulinemia.
- Novel agent safety profiling
- Combination regimens with monoclonal antibodies
- Response‑adapted treatment pathways
Efforts aim to improve survival outcomes in aggressive blood cancers.
Autoimmune and Inflammatory Diseases
Clinical studies on systemic lupus erythematosus, lupus nephritis, ulcerative colitis, Crohn’s disease and systemic sclerosis.
- Mechanistic exploration of immune pathways
- Evaluation of biologic and small‑molecule modulators
- Endpoints centered on organ preservation
These projects address unmet needs in chronic inflammatory conditions.
Cardiovascular and Metabolic Disorders
Trials targeting atherosclerotic cardiovascular disease, atrial fibrillation, hypertension and hypertriglyceridemia.
- Preventive therapy assessment
- Risk‑reduction strategies in high‑risk populations
- Integration of lipid‑lowering and anti‑arrhythmic agents
Work emphasizes reduction of major adverse cardiovascular events.
Rare Kidney and Complement Disorders
Focused research on C3 glomerulopathy, IgA nephropathy and immune‑complex membranoproliferative glomerulonephritis.
- Complement pathway inhibition
- Proteinuria reduction outcomes
- Long‑term renal function preservation
Studies aim to translate novel complement therapeutics into clinical practice.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.